“showed a trend”

In multivariable analysis, comorbid cannabis use disorder remained independently associated with PG (adjusted OR≈9.1; p=0.021), whereas longer opioid duration showed a trend-level association (p≈0.10).

In addition, FSH vaccination also showed a trend to downregulate mRNA expression of Tjp1 and Hey1 in testis ( p < 0.1). 3.5.

On the second day, the AMP group still showed a trend of lower CSS scores compared to the CON group ( p < 0.10). 3.4.

In univariate logistic regression, higher levels of folate at baseline and at five-years showed a trend association with a lower conversion rate to dementia (p<0.10; Table 4 ).

If a model showed a statistically significant effect on the Group or if the Group was close to being significant ( p < 0.1), we performed an unplanned multiple comparison test (Tukey HSD) to figure out which of the three groups differed ( p < 0.05) or showed a trend of difference ( p < 0.1).

Of the genes analyzed in EXP 1 following variable AFB1 exposure, NFE2L2 showed a trend ( P < 0.10) with a significantly reduced expression in the AFB1 high group compared to the unexposed group.

Consistent with observations in AD, dMBP staining showed a trend toward increased coverage in the WM of E4 LBD brains compared with E3 brains ( p = 0.10), although substantial inter-sample variability was observed (Fig. 6 h, i).

Only explanatory and confounding variables that showed a trend toward an association (eg, P < .10) with the outcome of interest in the univariate analysis were included in the multiple regression analysis.

The rare alleles of InsCCG243 in exon 2 showed a trend to over-representation among African American diabetic subjects (p < 0.1), but this trend was not significant on permutation test.

Among those AAs where uptake was inhibited by L-Met, a significant sodium × cis -inhibition effect was present for Trp and Ser ( p ≤ 0.05), while Val, Gln and Thr showed a trend for a sodium × cis -inhibition effect (0.05 < p ≤ 0.10).

However, twenty additional metabolites showed a trend towards differential abundance at a relaxed stringency ( p -value < 0.1), with most showing fold changes smaller but in the same direction as in Maf1 −/− mice, pointing to effects on the same pathways.

It should be noted that the p-value of our data only showed a trend of significance (p < 0.1).

TgAb showed a trend toward being positively associated with symptomatic hand OA ( p < 0.10).

Predictors that showed a trend ( P <0.1) that differed in the univariate test were included in the multivariable logistic regression.

Similarly, miR-142-3p showed a trend ( p < 0.1) towards increased expression in the high ACE group (Supplementary Fig. 4 ).

However, the sleep questionnaire Oguri–Shirakawa–Azumi Sleep Inventory, the Middle-age and Aged version (OSA-MA), administered immediately after waking showed a trend toward increased satisfaction with sleep time ( p < 0.1), and EEG measurements indicated significantly shortened wake-up times after waking with matcha intake ( p < 0.05).

Further analysis of the data by AUC revealed that during the immunization phase, the expression of CCR7 showed a trend (p ≤ 0.1) to increase in cT FH 2 but not cT FH 1 or cT FH 17 in TD compared with NoTD participants ( Supplementary Figures S5A-C ).

While TAVI also showed a trend toward reduced mortality, this was not statistically significant [2.1% vs. 3.7%; RR 0.99, 95% CI (0.97–1.00), p = 0.1].

To limit the number of exploratory tests, these were only performed on sleep or circadian variables that showed a trend-level association ( p < 0.1) with caregiver ZBI score in the initial regression model.

The immunoblot quantification demonstrated that CD44 protein expression showed a trend of upregulation at 4 weeks ( P = .1) and was significantly upregulated at 8 weeks ( P ≤ .001) (Fig. 1 D).

At day 0.5, the expression of Opn1sw showed a trend to decrease after MNU-S treatment ( p = 0.10) while no difference from control was observed after MNU-T and MMS treatment (Fig. 3 A).

Similarly, no significant association was observed between age groups and the risk of mild or moderate cognitive impairment, although adults aged >75 years showed a trend toward increased risk of moderate cognitive impairment (aOR = 2.76, 95% CI: 0.82-9.24, P = 0.100) compared to those aged 60–64 years.

Antipsychotic treatment showed a trend of a longer duration in serious versus non-serious reactions (22.00 days, quartile 1–3 [Q1–Q3] 12.00–46.00, vs. 16.00 days, Q1–Q3 4.00–23.00, p = 0.10).

Specifically, RBC: mem was positively correlated with EF ( ρ = 0.67, p = 0.03) and showed a trend with total cognitive composite score ( ρ = 0.55, p = 0.10).

498 Additionally, this group showed a trend towards superior 2-year survival ( P = 0.10), with median OS of 39.1 months for 10 μM trabedersen, 35.2 months for 80 μM trabedersen, and 21.7 months for chemotherapy. 498 In the realm of cancer vaccines, belagenpumatucel-L, a vaccine by NovaRx composed of NSCLC cells with a TGF-β2 antisense gene,